HCA Healthcare exhibits robust fundamental momentum with revenue growing from $58.8B in 2021 to $75.6B in 2025 and diluted EPS rising to $28.38, yet the stock has sold off sharply to $392.63, leaving it deeply oversold (RSI 14 at 24.4) and trading at a significant discount to peers (P/E of 13.1 vs. peer median 21.8). This valuation disconnect is compelling, but heavy net insider selling of 37 million shares over the past 24 months and a highly leveraged balance sheet with negative equity of -$6.0B introduce caution. The hold rating balances deep value against unresolved technical and sentiment headwinds.
Leverage and Negative Equity
Total debt rose to $50.2B in 2025 while stockholders' equity fell to -$6.0B, leaving the company vulnerable to rising interest costs or cash flow disruptions.
Persistent Insider Selling
Insiders disposed of a net 37 million shares over 24 months, which may signal lack of confidence despite recent grant-based acquisitions.
Technical Breakdown Risk
The stock is trading well below both the 50-day ($456.80) and 200-day ($462.44) moving averages with bearish MACD, and a failure to hold current levels could accelerate declines.
Regulatory and Reimbursement Changes
As a hospital operator, HCA is exposed to shifts in government healthcare policy and payer mix that could pressure margins.